Jula Inrig Sells 2,066 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 2,066 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $19.10, for a total value of $39,460.60. Following the transaction, the insider now owns 59,883 shares of the company’s stock, valued at approximately $1,143,765.30. This trade represents a 3.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jula Inrig also recently made the following trade(s):

• On Monday, January 6th, Jula Inrig sold 440 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.76, for a total value of $8,254.40.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $19.00 on Thursday. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The business’s 50 day moving average price is $18.17 and its two-hundred day moving average price is $14.02. The company has a market cap of $1.48 billion, a PE ratio of -4.18 and a beta of 0.70. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $20.33.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The company had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. During the same period in the previous year, the company posted ($1.17) EPS. The firm’s revenue for the quarter was up 69.6% compared to the same quarter last year. On average, analysts predict that Travere Therapeutics, Inc. will post -3.94 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on TVTX shares. Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $9.00 to $27.00 in a research report on Monday, October 21st. JPMorgan Chase & Co. boosted their price objective on shares of Travere Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Bank of America increased their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Leerink Partners reiterated an “outperform” rating and issued a $20.00 price target on shares of Travere Therapeutics in a research note on Tuesday, October 8th. Finally, HC Wainwright reduced their price objective on shares of Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, September 27th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.67.

Hedge Funds Weigh In On Travere Therapeutics

Several large investors have recently modified their holdings of the stock. CWM LLC boosted its holdings in shares of Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after buying an additional 3,065 shares during the period. DRW Securities LLC acquired a new stake in Travere Therapeutics during the second quarter worth approximately $95,000. Quarry LP bought a new stake in shares of Travere Therapeutics during the third quarter worth approximately $105,000. Forefront Analytics LLC grew its position in shares of Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after purchasing an additional 1,237 shares during the last quarter. Finally, Sei Investments Co. bought a new position in shares of Travere Therapeutics during the second quarter worth approximately $117,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.